JF
ATXS

Jump Financial’s Astria Therapeutics ATXS Stock Holding History

Jump Financial’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,193
Closed -$424K – 1767
2025
Q2 		$424K Buy
79,193
+45,888
+138% +$222K ﹤0.01% 1290
2025
Q1 		$178K Buy
+33,305
New +$233K ﹤0.01% 1446
2024
Q3 		– Sell
-68,697
Closed -$625K – 1638
2024
Q2 		$625K Buy
+68,697
New +$671K 0.01% 1040
2023
Q4 		– Sell
-14,926
Closed -$111K – 1775
2023
Q3 		$111K Buy
+14,926
New +$127K ﹤0.01% 1660
2023
Q1 		– Sell
-18,291
Closed -$272K – 1571
2022
Q4 		$272K Buy
18,291
+6,291
+52% +$64.9K 0.01% 1102
2022
Q3 		$108K Buy
+12,000
New +$80.4K ﹤0.01% 1436

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Jump Financial's ATXS Position: Q3 2025 in Review

Jump Financial sold out of Astria Therapeutics (ATXS) in Q3 2025, closing a stake of 79,193 shares — an estimated $424K sold.

Jump Financial first reported a position in ATXS in Q3 2022 and held it in 6 quarters. The position peaked at $625K in Q2 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q3 2025.

  • Jump Financial reported no remaining Astria Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jump Financial sold 79,193 Astria Therapeutics shares in Q3 2025, an estimated $424K.
  • Jump Financial first reported a position in Astria Therapeutics in Q3 2022 and held it in 6 quarters.
  • Jump Financial's Astria Therapeutics position peaked at $625K in Q2 2024.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.